

ForPatients

by Roche

Multiple Sclerosis (MS)

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

Trial Status

Active, not recruiting

Trial Runs In

1 Countries

Trial Identifier

NCT03972306 CN41144

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS).

Hoffmann-La Roche

Sponsor

Phase 1

Phase

NCT03972306 CN41144

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years & <= 65 Years

Healthy Volunteers

No
